Entero Healthcare Solutions Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 6 Aug 2026 | Retailing | Market Cap: ₹5.5K Cr
Organic growth estimated at 1.5x industry growth; sustainable growth expected beyond acquisitions. FY27 expected to be far better than FY26, driven by full-year impact of acquisitions made in FY26 and organic growth (Page 14).
From Entero Healthcare Solutions Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,424
Market Cap
₹5.5K Cr
P/E Ratio
46.3
How does Entero Healthcare Solutions Ltd rank in Retailing?
Compare Entero Healthcare Solutions Ltd against every Retailing company this quarter on revenue, margins and earnings-call signals.
Entero Healthcare Solutions Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.9K Cr, net profit ₹45 Cr.
Full financials →📊 Revenue & Sales Performance
- →Organic growth estimated at 1.5x industry growth; sustainable growth expected beyond acquisitions.
- →FY27 growth to be better than FY26 due to full-year impact of H2 FY26 acquisitions plus organic growth.
- →Next year’s growth driven by acquisition impact and organic expansion, with no material slowdown anticipated.
- →MedTech segment seen as a large growth opportunity with potential for faster growth due to pan-India exclusive distribution deals.
- →Existing warehouse infrastructure and relationships with pharma companies provide leverage for further growth.
- →Continuous expansion through acquiring companies that add unique geographies or product segments.
- →Focus on wallet share increase in existing customers and cross-selling to newly acquired customers.
- →Portfolio expansion with ~87,000 SKUs and over 3,000 companies supports wide market reach.
- →Retailers benefit from large consolidated product offerings and frequent deliveries, enhancing stickiness and growth.
📈 Profitability & Margins
- →FY27 expected to be far better than FY26, driven by full-year impact of acquisitions made in FY26 and organic growth (Page 14).
- →Operating cash flow (OCF) for FY26 targeted at INR100 crores, requiring strong positive cash flow in Q4; full-year cash flow projections maintained (Pages 18, 10).
- →EBITDA margin guidance maintained at 4% for FY26 with expectation to cross 4.5% in Q4 (Page 10).
- →MedTech segment acquisitions expected to improve gross margin by 70-90 basis points and EBITDA margin by 50-75 basis points on a pro forma basis (Page 8).
- →Longer-term organic growth levers include increasing wallet share, cross-selling acquired customers, and offering a vast product portfolio, supporting 1.5x industry growth rate sustainably (Page 15).
- →Growth for FY27 will come from organic growth plus acquisition impact from FY26; acquisition plans for FY27 are limited to consolidation (Page 14).
- →Confident on maintaining faster than industry revenue growth and margin expansion with robust last-mile distribution and new segment capabilities (Pages 3, 9).
🏗️ Capital Expenditure Plans
💰 Fundraising & Capital Structure
- →The company has broadly completed all big acquisitions as of now.
- →Currently, there are no plans to raise any equity capital.
- →There could be some movement in debt, but no indication of significant new debt raising.
- →The focus for the next few quarters will be on consolidating existing acquisitions, stabilizing operations, improving margins, and cash flows.
- →Further meaningful acquisitions are not planned immediately; any new fundraising would likely be aligned with future acquisitions after stabilization.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Entero Healthcare Solutions Ltd Q3 FY26 results?
Organic growth estimated at 1.5x industry growth; sustainable growth expected beyond acquisitions. FY27 expected to be far better than FY26, driven by full-year impact of acquisitions made in FY26 and organic growth (Page 14).
What is Entero Healthcare Solutions Ltd share price analysis?
Entero Healthcare Solutions Ltd currently shows a neutral. The stock trades at a P/E of 46.3 with a market cap of ₹5,479 Cr. Investors should review the full earnings analysis for detailed insights.
Is Entero Healthcare Solutions Ltd planning capital expenditure?
The business is not capital intensive; most warehouses are leased.
Keep Entero Healthcare Solutions Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
